Nautilus Biotechnology (Nautilus Biotechnology) Debt-to-Equity : 0.14 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Debt-to-Equity?

Nautilus Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.68 Mil. Nautilus Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $29.95 Mil. Nautilus Biotechnology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $249.49 Mil. Nautilus Biotechnology's debt to equity for the quarter that ended in Mar. 2024 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nautilus Biotechnology's Debt-to-Equity or its related term are showing as below:

NAUT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.16 Med: 0.09 Max: 0.14
Current: 0.14

During the past 4 years, the highest Debt-to-Equity Ratio of Nautilus Biotechnology was 0.14. The lowest was -0.16. And the median was 0.09.

NAUT's Debt-to-Equity is ranked better than
51.78% of 1066 companies
in the Biotechnology industry
Industry Median: 0.15 vs NAUT: 0.14

Nautilus Biotechnology Debt-to-Equity Historical Data

The historical data trend for Nautilus Biotechnology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nautilus Biotechnology Debt-to-Equity Chart

Nautilus Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.16

0.08

0.10

0.13

Nautilus Biotechnology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial											0.12	0.13	0.13	0.13	0.14

Competitive Comparison of Nautilus Biotechnology's Debt-to-Equity

For the Biotechnology subindustry, Nautilus Biotechnology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nautilus Biotechnology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's Debt-to-Equity falls into.

Nautilus Biotechnology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nautilus Biotechnology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.538	+	31.09)	/	265.353
	=	0.13

Nautilus Biotechnology's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.675	+	29.946)	/	249.492
	=	0.13

Nautilus Biotechnology (NAS:NAUT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nautilus Biotechnology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nautilus Biotechnology (Nautilus Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2701 Eastlake Avenue East, Seattle, WA, USA, 98102

Website

https://www.nautilus.bio

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.

Executives

Michael Seth Altman	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar	officer: Senior VP, Product Development	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld	officer: Chief People Officer	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry	officer: CFO and Treasurer	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy	officer: General Counsel	C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Sujal M Patel	director, 10 percent owner, officer: CEO, President, and Secretary	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin	officer: Senior VP, Operations	3101 WESTERN AVENUE, SEATTLE WA 98121
Karen Akinsanya	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain	director	1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Benjamin A Horowitz	10 percent owner	2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Marc L Andreessen	10 percent owner	C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111